t-butyl 2-{[(3-fluoro-4-hydroxyanilino)carbothioyl]amino}ethylcarbamate | 915404-97-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: t-butyl 2-{[(3-fluoro-4-hydroxyanilino)carbothioyl]amino}ethylcarbamate
• 英文别名: tert-butyl N-[2-[(3-fluoro-4-hydroxyphenyl)carbamothioylamino]ethyl]carbamate
• CAS: 915404-97-6
• 化学式: C₁₄H₂₀FN₃O₃S
• 分子量: 329.396
• InChiKey: XPOKMPROXPDMIY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  115
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-叔丁氧羰基-1,2-乙二胺 、 4-氨基-2-氟苯酚 在 sodium hydroxide 、 水 作用下， 以 甲苯 、 水 为溶剂， 反应 3.5h， 生成 t-butyl 2-{[(3-fluoro-4-hydroxyanilino)carbothioyl]amino}ethylcarbamate
  参考文献：
  名称：

  EP1875915

  摘要：

  公开号：

文献信息

• THERAPEUTIC AGENT FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  申请人：Dainippon Sumitomo Pharma Co., Ltd.

  公开号：EP1875915A1

  公开（公告）日：2008-01-09

  Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.

  本发明涉及一种通过给予下式表示的5元环化合物的预防和/或治疗慢性阻塞性肺疾病的方法：或其药学上可接受的盐或其前药物，其中X代表氧原子或硫原子; R1代表氢原子、取代或未取代的烷基或类似物; R2代表氢原子、取代或未取代的烷基或类似物; Y1代表单键、取代或未取代的脂肪基或类似物; 波浪线表示（E）或（Z）配位; R3代表氢原子、取代或未取代的芳基或类似物; Y2代表取代或未取代的脂肪基或烯基; R4代表氢原子、取代或未取代的烷酰基或类似物; R5代表氢原子或取代或未取代的烷基。
• Therapeutic agent for chronic obstructive pulmonary disease
  申请人：Sugasawa Toshinari

  公开号：US20090131439A1

  公开（公告）日：2009-05-21

  Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R 1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R 2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y 1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R 3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y 2 represents a substituted or unsubstituted alkylene or an alkenylene; R 4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R 5 represents a hydrogen atom or a substituted or unsubstituted alkyl.

  本发明公开了一种通过给予下式所表示的5元环化合物的药物或其盐或其前药的方法，用于预防和/或治疗慢性阻塞性肺疾病：其中X代表氧或硫原子；R1代表氢原子，取代或未取代的烷基或类似物；R2代表氢原子，取代或未取代的烷基或类似物；Y1代表单键，取代或未取代的亚烷基或类似物；波浪线表示（E）或（Z）配位；R3代表氢原子，取代或未取代的芳基或类似物；Y2代表取代或未取代的亚烷基或烯基；R4代表氢原子，取代或未取代的脂肪酰基或类似物；R5代表氢原子或取代或未取代的烷基。
• US8012971B2
  申请人：——

  公开号：US8012971B2

  公开（公告）日：2011-09-06
• EP1875915
  申请人：——

  公开号：——

  公开（公告）日：——